Surveillance of pancreatic cancer patients after surgical resection

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1670-1677

  Sheffield, Kristin M ^a   Crowell, Kristen T ^a   Lin, Yu Li ^b   Djukom, Clarisse ^a   Goodwin, James S ^a,b   Riall, Taylor S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENERAL PRACTITIONER; HOSPICE CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; SYMPTOM; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; CAUSE OF DEATH; CHEMORADIOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MEDICARE; NEOPLASM RECURRENCE, LOCAL; OFFICE VISITS; PANCREATIC NEOPLASMS; POPULATION SURVEILLANCE; POSTOPERATIVE PERIOD; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 84862548711     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2152-y     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586-94. (Pubitemid 38624667)
3. Hattangadi JA, Hong TS, Yeap BY, Mamon HJ. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer. 2009;115:3640-50.
4. Hernandez JM, Morton CA, Al-Saadi S, et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. Am Surg. 2010;76:480-5.
5. Asiyanbola B, Gleisner A, Herman JM, et al. Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg. 2009;13:752-9.
6. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511-8. (Pubitemid 43619152)
7. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246:52-60. (Pubitemid 47012207)
8. Kinsella TJ, Seo Y, Willis J, et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol. 2008;31:446-53.
9. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21:195-200. (Pubitemid 27053441)
10. Wertheimer MD. Against minimalism in breast cancer follow-up. JAMA. 1991;265:396-7.
11. Wilkowski R, Thoma M, Bruns C, Duhmke E, Heinemann V. Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP. 2006;7:34-40. (Pubitemid 43103797)
12. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35: 600-4.
13. Kang CM, Kim JY, Choi GH, et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007;140:31-5. (Pubitemid 46669540)
14. NCCN (National Comprehensive Cancer Network). NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, v.2.2010. 2010. http://www.nccn.org.
15. Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007;25:1074-81. (Pubitemid 46596759)
16. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001;19:1064-70. (Pubitemid 32176282)
17. Lafata JE, Simpkins J, Schultz L, et al. Routine surveillance care after cancer treatment with curative intent. Med Care. 2005;43: 592-9. (Pubitemid 40847296)
18. Knopf KB, Warren JL, Feuer EJ, Brown ML. Bowel surveillance patterns after a diagnosis of colorectal cancer in Medicare beneficiaries. Gastrointest Endosc. 2001;54:563-71. (Pubitemid 33666027)
19. Cooper GS, Johnson CC, Lamerato L, et al. Use of guideline recommended follow-up care in cancer survivors: routine or diagnostic indications? Med Care. 2006;44:590-4. (Pubitemid 44284298)
20. Hewitt ME, Greenfield S, Stovall E; National Cancer Policy Board (US). Committee on Cancer Survivorship: Improving Care and Quality of Life. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press, 2006.
21. Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26:1073-9.
22. Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006;24:85-94. (Pubitemid 46630498)
23. Kleeff J, Reiser C, Hinz U, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007;245:566-72. (Pubitemid 46555660)
24. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA. 2010;303:1625-31.
25. Cooper GS, Schultz L, Simpkins J, Lafata JE. The utility of administrative data for measuring adherence to cancer surveillance care guidelines. Med Care. 2007;45:66-72.